Before suggesting a merger of Resverlogix and Zenith, lets wait to hear their respective AGMs.

Resverlogix AGM on 9/30.

Zenith AGM date is still to be determined. Per Sarah, Zenith will still have their AGM this year, but "the date has not been finalized. Once this information is ready for the public they will post it to the website."

Although the two companies are both focused on BET inhibitors, the clinical focus of the two companies was quite distinct at the time of the initial spin off. Hopefully the AGMs will provide clarity for us to conclude that the two companies are still clinically diverse.